Nuwellis Q4 revenue record $2.6M (+9% YoY); net loss $7.9M on financing costs; pediatric sales up 35%

Nuwellis, Inc.

Q4 revenue $2.6M (+9% YoY); full year revenue $8.9M (+4% YoY).
Net loss attributable to common $7.9M ($2.24/share) includes $4.4M financing-related charges; prior year net loss $1.9M.
Pediatric revenue +35% YoY in Q4; utilization +28%, console sales +49%, 4 new accounts added.
Cash $3.8M, no debt; CEO targets 40% cash-burn reduction and expects capital raise in 2024.
New products launched: 12cm dELC catheter, Quelimmune pediatric device; IDE submission for Vivian device planned.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nuwellis, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $2.6 million, net income net loss attributable to common shareholders of $7.9 million, EPS loss of $2.24 per basic and diluted common share.

Period: fourth quarter and full year ended December 31, 2023
Revenue: $2.6 million
Net income: net loss attributable to common shareholders of $7.9 million
EPS: loss of $2.24 per basic and diluted common share
Result: reported results

Exact text from the filing

the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2023. Highlights: ● Record quarter revenue of $2.6 million, a 9% increase over prior-year period. Full year revenue of $8.9 million, a 4% increase over 2022. ● Fourth quarter pediatric revenue grew 35% year over year; 28% increase in

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuwellis, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-011633

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.